POSITIVE
Clinical Trial Program
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).
Phase 0
Status
Recruiting
Tumour subtype:
HR+
Scenario
Study, no clinical trial no PAS (Post Approval Studies; without drug)
PRINCIPAL INVESTIGATORS
Olivia Pagani, MD (Oncology Institute of Southern Switzerland (IOSI))
Ann Partridge MD MPH (Dana-Farber Cancer Institute)
Hatem A. Azim Jr., MD, PhD (Institut Jules Bordet)
Fedro Peccatori, MD, PhD (European Institute of Oncology)
Sites
HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL DE FUENLABRADA, HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA, HOSPITAL QUIRONSALUD SAGRADO CORAZON, HOSPITAL SON ESPASES, HOSPITAL UNIVERSITARI GENERAL DE CATALUNYA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, CENTRO CLÍNICO FUNDAÇAO CHAMPALIMAUD
